// App-Quantinova.ai

5052 : First-in-human phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide (LNA-ASO) to androgen receptor (AR) mRNA in patients with castration-resistant prostate cancer (CRPC).

Researchers

Presenter

  • Diletta Bianchini

Principal Investigators

  • Aurelius Gabriel Omlin

  • Carmel Jo Pezaro

  • Johann Sebastian De Bono

  • Daniel Costin Danila

  • Deborah Mukherji

  • David Lorente Estelles

  • Andrea Zivi

  • Roberta Ferraldeschi

  • Mateus Crespo

  • Aby Buchbinder

  • Gerhardt Attard

  • Howard I. Scher

Medical Centers

  • Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Invivis Pharmaceuticals, Bridgewater, NJ

  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

  • Institute for Cancer Research, London, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • Enzalutamide

  • CB-7598

  • Androgen Tear

  • EZN-4176

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT01337518

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved